Eribulin Mesylate Injection
Product Images NDC 0143-9167

5 FDA label images from Hikma Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 0143-9167). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Eribulin Structure)

Structural Formula (Eribulin Structure)
Chemical structure diagram of eribulin mesylate, showing its molecular framework and functional groups with chemical bond representations.*
FDA Label Image

Figure 1 (Eribulin Fig1)

Figure 1 (Eribulin Fig1)
A Kaplan-Meier survival curve comparing the proportion of patients alive over time in months for Eribulin Mesylate Injection (N=508) versus a control group (N=254). The vertical axis represents the proportion of patients alive, while the horizontal axis shows time in months up to 36 months. The graph includes a table showing the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 2 (Eribulin Fig2)

Figure 2 (Eribulin Fig2)
A Kaplan-Meier survival curve comparing survival probability over time (months) between Eribulin Mesylate Injection and Dacarbazine. The graph plots survival probability on the y-axis against survival time in months on the x-axis, with Eribulin Mesylate Injection shown as a solid blue line and Dacarbazine as a dashed red line. The plot includes numbers of subjects at risk for each treatment at various time points below the x-axis.*
FDA Label Image

Eribulin Vial Label (Eribulin Vial02)

Eribulin Vial Label (Eribulin Vial02)
Label for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL), an intravenous sterile solution manufactured by Jiangxi Kwuit Pharmaceutical Co., Ltd. and distributed by Hikma Pharmaceuticals USA Inc. The label includes storage instructions, dosing caution, and batch lot/expiration sections. The product is indicated for prescription use only.*
FDA Label Image

Eribulin Carton Label (Eribulin Carton02)

Eribulin Carton Label (Eribulin Carton02)
Packaging label for Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) sterile solution for intravenous use. The label states that it is a single-dose vial with a cytotoxic agent caution. Manufactured for Jiangxi Kvidt Pharmaceutical Co., Ltd. and distributed by Hikma Pharmaceuticals USA Inc. The design includes orange and olive-green color blocks with the Hikma logo at the bottom and a barcode on one panel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.